Validation of Ultra-Widefield Autofluorescence Imaging as an Endpoint for Disease Progression in Choroideremia: A Comparative Study

Mechteld CS van Olden, Jeroen AAH Pas, Suzanne Yzer, Carel B Hoyng, Thomas Theelen · 2026

Read Validation of Ultra-Widefield Autofluorescence Imaging as an Endpoint for Disease Progression in Choroideremia: A Comparative Study by Mechteld CS van Olden, Jeroen AAH Pas, Suzanne Yzer, Carel B Hoyng, Thomas Theelen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13527496.txt.

Description

Mechteld C. S. van Olden and colleagues validate, in a 2026 retrospective study, ultra-widefield autofluorescence imaging as a way to track disease progression in choroideremia, an inherited retinal wasting disease. Gene therapy trials in this condition missed their main vision endpoint, yet treatment effects in the far periphery might have gone unnoticed. Widefield imaging can capture that periphery.

Ninety-six images from fifteen patients with genetically confirmed disease were compared, pairing conventional thirty- or fifty-five-degree views with ultra-widefield images taken the same day. Two graders outlined atrophic areas and surviving pigment epithelium islands, with agreement ranging from good to excellent. Within the central field, total and atrophy measurements matched closely between methods, while preserved islands differed slightly in the narrower view. The authors support widefield imaging as a trial endpoint.

Catalog record

CREATORMechteld CS van Olden, Jeroen AAH Pas, Suzanne Yzer, Carel B Hoyng, Thomas Theelen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13527496

Browse the full library · About the Tower of Babel